-
Mashup Score: 0
Combined BRAF + MEK inhibition is FDA approved for BRAF V600E-mutant solid tumors except for colorectal cancer. However, beyond MAPK mediated resistance several other mechanisms of resistance such as activation of CRAF, ARAF, MET, P13K/AKT/mTOR pathway exist among other complex pathways. In the VEM-PLUS study, we performed a pooled analysis of four phase one studies evaluating the safety and…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 02022 FDA Approvals of Drugs for Cancer Treatment - 2 year(s) ago
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to many novel drugs and new indications for older therapeutic agents used in oncology and hematology. Here is a comprehensive list of FDA approvals as of December 22, 2022. ❖ December …
Source: contentsharing.netCategories: Hem/Oncs, Latest HeadlinesTweet-
Quite a number of @US_FDA approvals in oncology in 2022 https://t.co/qeRdzpy2Hj
-
-
Mashup Score: 0Speedier drug approvals hit slowdown as FDA faces scrutiny - 2 year(s) ago
WASHINGTON (AP) — Expedited drug approvals slowed this year as the Food and Drug Administration’s controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders.
Source: AP NEWSCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/ZZnDhF2Mbj
-
-
Mashup Score: 0FDA approves olutasidenib - 2 year(s) ago
FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation
Categories: Hem/Oncs, Latest HeadlinesTweet-
Breaking News! Another #IDHinhibitor receives #FDAapproval for IDH1-mutated R/R #AML https://t.co/QKh65BANri https://t.co/zRyusbOXuJ
-
-
Mashup Score: 0Knowledge generalization and the costs of multitasking - Nature Reviews Neuroscience - 2 year(s) ago
When humans attempt two tasks at once, there are costs to task performance. In this Perspective, Garner and Dux discuss neurophysiological evidence for whether these multitasking costs are linked to the human capability for rapid knowledge generalization to perform novel tasks.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Walk and chew gum at the same time? Not without consequences according to this Perspective in @NatRevNeurosci. The Good, the Bad and the ugly of #multitasking https://t.co/cOXhn3gzML
-
-
Mashup Score: 0Filip Janku (@CancerDoc@med-mastodon.com) - 2 year(s) ago
If there is anyone still thinking that #BREXIT was a good idea then please read this #LancetRH_Europe editorial. UK faces: * 41% reduction in industry-led clinical trials between 2017 and 2021 * NHS is grappling with 130,000 vacancies * UK has been temporarily barred access to €95.5 billion of funding from the EU Horizon (before Brexit, the UK got most funds after Germany in receiving…
Source: Med-MastodonCategories: Hem/Oncs, Latest HeadlinesTweet-
Do you think #Brexit was great? Think again. Some facts about the impact on #healthscience in @LancetRH_Europe editorial. ❗️⬇️41% in industry-led clinical trials ❗️130,000 NHS vacancies ❗️temporarily no access to €95.5B from EU Horizon https://t.co/DkTCaL17LI
-
-
Mashup Score: 0Carl Zimmer (@Carl_Zimmer@mastodon.social) - 2 year(s) ago
An impressive visualization of the SARS-CoV-2 life cycle. https://www.youtube.com/watch?v=XlOi2hVGtg0&t=2s
Source: MastodonCategories: Hem/Oncs, Latest HeadlinesTweet-
Fascinating visualization of SARS-CoV2 virus 🦠 life cycle on #mastodon https://t.co/GaU5uScJQM
-
-
Mashup Score: 6
General Sessions Hall E (Ernest N. Morial Convention Center) Co-chairs: David A. Garcia, MD, University of Washington and Olatoyosi Odenike, MD, University of Chicago Disclosures: No…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @patrickreville: @dgermain21 @ASH_hematology https://t.co/gKgc40WJZ8
-
RT @JacobPlieth: #ASH22 late-breakers are up https://t.co/D4YEIq5geZ
-
-
Mashup Score: 1Blenrep for Multiple Myeloma Withdrawn From US Market - 2 year(s) ago
The manufacturer is pulling the drug from the market at the request of the FDA following disappointing results from a large phase 3 confirmatory trial.
Source: MedscapeCategories: Hem/Oncs, Latest HeadlinesTweet-
#BCMA #ADC belanatamab withdrawn from the US. P3 confirmatory trial DREAMM3 (belantamab vs. PomDex) for #RRMM showed no PFS advantage (HR, 1.03; 95% CI, 0.72 – 1.47). #FDA #AcceleratedApproval mechanism works as it should!!! https://t.co/6zAp0pXgj7 https://t.co/AjKeDDnH2L
-
-
Mashup Score: 1Global and regional estimates of orphans attributed to maternal cancer mortality in 2020 - Nature Medicine - 2 year(s) ago
According to 2020 estimates from 185 countries, Asia and Africa have the most maternal orphans due to cancer, with breast and cervical cancers responsible for almost half of maternal cancers.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
#EndCancer #CancerScreening https://t.co/Usk4Eu8B1W https://t.co/1vyEQtsj4K
-
RT @VivekSubbiah: Open access paper - free for all to read @Nature_NPJ https://t.co/VZZnnG2aGp https://t.co/iGed61flg5